I’ve Got My Mind Set on a Cure!

Michael Tuohy |

If you have not yet noticed, I’m a fan of good music. I’ve had bands since the 70s, growing up with what’s now called classic rock. Funny how time goes by, and it’s now “classic.” I guess it’s a good thing, because I grew up in a time when music had leads and lyrics that […]

Summary of ASH 2018

Jack Aiello |

December 4, 2018 Before presenting my ASH summary, I’ll mention a late-breaking abstract presentation that I was unable to attend early this morning focused on a phase III trial using Darzalex (daratumumab) in front-line therapy plus Rev-dex versus Rev-dex only for transplant-ineligible patients. The abstract # LBA-2 showed that the addition of Dara decreased the […]

Day 3 – Saving the Best for Last

Jack Aiello |

December 3, 2018 Yes, today was the last full day of ASH, but that’s not to say it wasn’t full of information with oral presentations packing the day from 7:00 a.m.–7:45 p.m. Highlights included (# abstract number): Isatuximab-Vel-Rev-dex (Isa-VRd) for Newly Diagnosed Non-stem-cell-transplant-eligible myeloma patients (#595): This four-drug phase I study for 27 patients reported […]

Day 2: A Busy Day at ASH

Jack Aiello |

Day 2: A busy day at ASH December 2, 2018 Today I attended oral presentations from 8 a.m. to 6 p.m. with a few short breaks to check out posters and exhibits as well as meet with Pharma companies. Let me discuss several findings from several oral presentations (#abstract). Maintenance Therapy with Ninlaro (Ixazomib)….Tourmaline 3 […]